Respiratory investigation最新文献_第4页

Impact of hospitalization on health-related quality of life in patients receiving home oxygen therapy: Insights of the Japanese white paper on home respiratory care 2024 住院治疗对接受家庭氧疗患者健康相关生活质量的影响：日本家庭呼吸护理白皮书2024的见解

IF 2 Q2 RESPIRATORY SYSTEM

Respiratory investigation

Pub Date : 2025-11-29 DOI: 10.1016/j.resinv.2025.101341

Satoshi Hamada , Jun Ueki , Toyohiro Hirai , Emika Sano , Keiko Hino , Megumi Ikeda , Susumu Sato , Toru Oga , Tomomasa Tsuboi , Hajime Kurosawa , Hiroo Wada , the Japanese White Paper on Home Respiratory Care 2024 working group

Background

There are no available data on the impact of hospitalization on health-related quality of life (HRQoL) in patients receiving home oxygen therapy (HOT). Thus, the present study aimed to examine the association between hospitalization and HRQoL in patients receiving HOT based on the results of the Japanese White Paper on Home Respiratory Care 2024.

Methods

Patients receiving HOT who completed the HRQoL section of the patient survey, assessed using the Short Form-8 (SF-8) questionnaire, were included in the analysis. This survey data were collected from December 2021 to March 2023. The SF-8 questionnaire comprised eight subitems and two summary scores (physical component summary [PCS] and mental component summary [MCS]). Hospitalization within the past year were evaluated, excluding those due to coronavirus disease 2019.

Results

Totally, 288 patients receiving HOT were examined. In the SF-8 questionnaire survey, all items except body pain and the two summary scores did not differ between patients with chronic obstructive pulmonary disease and those with interstitial lung disease. Patients who had history of hospitalization had lower scores in all eight subitems and in both summary scores than those who did not. Based on a stepwise multiple linear regression analysis, PCS (β = −0.14, p = 0.011) and MCS (β = −0.14, p = 0.014) scores were independently and negatively correlated with hospitalization.

Conclusions

A history of hospitalization was independently associated with reduced HRQoL in patients receiving HOT. Prospective studies are needed to clarify underlying mechanisms and to evaluate interventions that may minimize HRQoL decline.

背景：目前尚无关于住院治疗对接受家庭氧疗（HOT）患者健康相关生活质量（HRQoL）影响的数据。因此，本研究旨在基于日本家庭呼吸护理白皮书2024的结果，探讨住院与接受HOT患者HRQoL之间的关系。方法接受HOT治疗的患者完成患者调查的HRQoL部分，使用SF-8问卷进行评估，纳入分析。该调查数据收集于2021年12月至2023年3月。SF-8问卷包括8个小项目和2个综合得分（生理成分总结[PCS]和心理成分总结[MCS]）。评估了过去一年内的住院情况，但不包括因2019年冠状病毒病住院的情况。结果共检查HOT患者288例。在SF-8问卷调查中，慢性阻塞性肺疾病患者与间质性肺疾病患者除身体疼痛和两项总结得分外，其他项目均无差异。有住院史的患者在所有八个分项和两项综合得分上的得分都低于没有住院史的患者。经逐步多元线性回归分析，PCS评分（β = - 0.14, p = 0.011）和MCS评分（β = - 0.14, p = 0.014）与住院治疗呈独立负相关。结论住院史与热疗患者HRQoL降低独立相关。需要前瞻性研究来阐明潜在的机制，并评估可能使HRQoL下降最小化的干预措施。

{"title":"Impact of hospitalization on health-related quality of life in patients receiving home oxygen therapy: Insights of the Japanese white paper on home respiratory care 2024","authors":"Satoshi Hamada , Jun Ueki , Toyohiro Hirai , Emika Sano , Keiko Hino , Megumi Ikeda , Susumu Sato , Toru Oga , Tomomasa Tsuboi , Hajime Kurosawa , Hiroo Wada , the Japanese White Paper on Home Respiratory Care 2024 working group","doi":"10.1016/j.resinv.2025.101341","DOIUrl":"10.1016/j.resinv.2025.101341","url":null,"abstract":"<div><h3>Background</h3><div>There are no available data on the impact of hospitalization on health-related quality of life (HRQoL) in patients receiving home oxygen therapy (HOT). Thus, the present study aimed to examine the association between hospitalization and HRQoL in patients receiving HOT based on the results of the Japanese White Paper on Home Respiratory Care 2024.</div></div><div><h3>Methods</h3><div>Patients receiving HOT who completed the HRQoL section of the patient survey, assessed using the Short Form-8 (SF-8) questionnaire, were included in the analysis. This survey data were collected from December 2021 to March 2023. The SF-8 questionnaire comprised eight subitems and two summary scores (physical component summary [PCS] and mental component summary [MCS]). Hospitalization within the past year were evaluated, excluding those due to coronavirus disease 2019.</div></div><div><h3>Results</h3><div>Totally, 288 patients receiving HOT were examined. In the SF-8 questionnaire survey, all items except body pain and the two summary scores did not differ between patients with chronic obstructive pulmonary disease and those with interstitial lung disease. Patients who had history of hospitalization had lower scores in all eight subitems and in both summary scores than those who did not. Based on a stepwise multiple linear regression analysis, PCS (β = −0.14, p = 0.011) and MCS (β = −0.14, p = 0.014) scores were independently and negatively correlated with hospitalization.</div></div><div><h3>Conclusions</h3><div>A history of hospitalization was independently associated with reduced HRQoL in patients receiving HOT. Prospective studies are needed to clarify underlying mechanisms and to evaluate interventions that may minimize HRQoL decline.</div></div>","PeriodicalId":20934,"journal":{"name":"Respiratory investigation","volume":"64 1","pages":"Article 101341"},"PeriodicalIF":2.0,"publicationDate":"2025-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145616022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Bronchoscopic lung insufflation for post-transplant lobar atelectasis: Efficacy and a rare complication of cerebral gas embolism 支气管镜下肺充气治疗移植后肺大叶不张：疗效和脑气栓塞的罕见并发症

IF 2 Q2 RESPIRATORY SYSTEM

Respiratory investigation

Pub Date : 2025-11-28 DOI: 10.1016/j.resinv.2025.101339

Yojiro Yutaka , Akira Matsumoto , Ichiro Sakanoue , Hidenao Kayawake , Satona Tanaka , Daisuke Nakajima , Hiroshi Date

Bronchoscopic lung insufflation (BLI) allows re-expansion of collapsed lung lobes after transplantation. Among 254 transplant cases at our center, two patients underwent BLI for lobar atelectasis. Case 1 had recurrent right middle-lobe collapse after initial recovery, and BLI under conscious sedation led to durable re-expansion without complications. Case 2 underwent BLI for right upper-lobe atelectasis but developed transient neurological deficits due to presumed cerebral gas embolism, despite initial re-expansion. Full recovery was achieved with supportive care. These cases highlight BLI as an effective treatment for post-transplant atelectasis, although rare but serious complications require careful monitoring.

支气管镜肺充气（BLI）允许移植后塌陷的肺叶重新扩张。在我们中心的254例移植病例中，有2例患者因肺叶不张而行BLI。病例1在初次恢复后复发右中叶塌陷，清醒镇静下的BLI导致持续的再扩张，无并发症。病例2因右上肺叶不张接受了BLI治疗，尽管最初再次扩张，但由于假定的脑气栓塞而出现了一过性神经功能障碍。在支持性护理下完全康复。这些病例强调BLI是移植后肺不张的有效治疗方法，虽然罕见但严重的并发症需要仔细监测。

引用次数: 0

A case of persistent pneumothorax after bronchoscopic lung volume reduction successfully treated with video-assisted thoracic surgery without removal of endobronchial valves 支气管镜下肺减容术后持续性气胸1例，经电视辅助胸外科手术治疗，无支气管内瓣切除

IF 2 Q2 RESPIRATORY SYSTEM

Respiratory investigation

Pub Date : 2025-11-26 DOI: 10.1016/j.resinv.2025.101338

Tadashi Sakaguchi , Tomohito Tarukawa , Yoichi Nishii , Motoshi Takao , Osamu Hataji

With proper patient selection excluding collateral ventilation, bronchoscopic lung volume reduction (BLVR) with endobronchial valves (EBVs) offers significant benefits but increases pneumothorax risk. Prioritized management of persistent pneumothorax post-BLVR remains unclear, with both EBV removal and video-assisted thoracic surgery (VATS) considered options. We report a 76-year-old man with severe emphysema who developed persistent pneumothorax and subcutaneous emphysema after left upper lobe BLVR. Following the patient's wishes, VATS was performed instead of EBV removal, resulting in a favorable outcome without delaying BLVR benefits. Depending upon the situation and patient wishes, prioritizing VATS over valve removal may be a reasonable strategy.

通过适当的患者选择，排除侧支通气，支气管镜下肺减容术（BLVR）与支气管内瓣膜（ebv）可以提供显着的益处，但增加气胸风险。blvr后持续性气胸的优先处理尚不清楚，EBV切除和视频辅助胸外科手术（VATS）都是考虑的选择。我们报告一位76岁男性严重肺气肿，在左上肺叶BLVR后出现持续性气胸和皮下肺气肿。根据患者的意愿，采用VATS代替EBV切除，在没有延迟BLVR益处的情况下获得了良好的结果。根据情况和患者的意愿，优先进行VATS而不是瓣膜移除可能是一个合理的策略。

引用次数: 0

How to choose a biologic agent considering comorbidities of bronchial asthma 考虑支气管哮喘的合并症，如何选择生物制剂

IF 2 Q2 RESPIRATORY SYSTEM

Respiratory investigation

Pub Date : 2025-11-26 DOI: 10.1016/j.resinv.2025.101337

Masamichi Itoga, Sadatomo Tasaka

Biologic therapies have revolutionized the treatment of severe asthma. However, the selection of the optimal biologic agent remains challenging because of the heterogeneity of disease phenotypes and frequent comorbidities. This mini-review explored the clinical relevance of comorbidities in the selection of biologics for patients with asthma.

Herein, we summarize recent evidence on the prevalence of comorbidities associated with type 2 inflammation, including chronic spontaneous urticaria, atopic dermatitis, prurigo nodularis, chronic rhinosinusitis with nasal polyps, eosinophilic granulomatosis with polyangiitis, eosinophilic otitis media, aspirin-exacerbated respiratory disease, allergic rhinitis, allergic bronchopulmonary mycosis, obesity, and chronic obstructive pulmonary disease, and review the efficacy of five major biologics (omalizumab, mepolizumab, benralizumab, dupilumab, and tezepelumab) in these settings. Each biologic targets distinct immunologic pathways in type 2 inflammation, including IgE, IL-5, IL-5Rα, IL-4Rα, and thymic stromal lymphopoietin, respectively.

In conclusion, the assessment of comorbidities in addition to biomarkers is essential for tailoring biologic therapies for severe asthma. Integrating comorbidity profiles into treatment strategies allows for a more precise and effective use of biologics, ultimately improving outcomes in complicated asthma cases.

生物疗法使严重哮喘的治疗发生了革命性的变化。然而，由于疾病表型的异质性和常见的合并症，选择最佳的生物制剂仍然具有挑战性。这篇小型综述探讨了哮喘患者选择生物制剂时合并症的临床相关性。在此，我们总结了最近与2型炎症相关的合并症患病率的证据，包括慢性自发性荨麻疹、特应性皮炎、结节性痒疹、伴鼻息肉的慢性鼻窦炎、伴多血管炎的嗜酸性肉芽肿病、嗜酸性中耳炎、阿司匹林加重的呼吸系统疾病、变应性鼻炎、过敏性支气管肺真菌病、肥胖和慢性阻塞性肺病。并回顾五种主要生物制剂（omalizumab, mepolizumab, benralizumab， dupilumab和tezepelumab）在这些情况下的疗效。在2型炎症中，每种生物制剂分别靶向不同的免疫途径，包括IgE、IL-5、IL-5Rα、IL-4Rα和胸腺基质淋巴生成素。总之，除了生物标志物外，评估合并症对于定制严重哮喘的生物疗法至关重要。将共病概况纳入治疗策略，可以更精确、更有效地使用生物制剂，最终改善复杂哮喘病例的预后。

{"title":"How to choose a biologic agent considering comorbidities of bronchial asthma","authors":"Masamichi Itoga, Sadatomo Tasaka","doi":"10.1016/j.resinv.2025.101337","DOIUrl":"10.1016/j.resinv.2025.101337","url":null,"abstract":"<div><div>Biologic therapies have revolutionized the treatment of severe asthma. However, the selection of the optimal biologic agent remains challenging because of the heterogeneity of disease phenotypes and frequent comorbidities. This mini-review explored the clinical relevance of comorbidities in the selection of biologics for patients with asthma.</div><div>Herein, we summarize recent evidence on the prevalence of comorbidities associated with type 2 inflammation, including chronic spontaneous urticaria, atopic dermatitis, prurigo nodularis, chronic rhinosinusitis with nasal polyps, eosinophilic granulomatosis with polyangiitis, eosinophilic otitis media, aspirin-exacerbated respiratory disease, allergic rhinitis, allergic bronchopulmonary mycosis, obesity, and chronic obstructive pulmonary disease, and review the efficacy of five major biologics (omalizumab, mepolizumab, benralizumab, dupilumab, and tezepelumab) in these settings. Each biologic targets distinct immunologic pathways in type 2 inflammation, including IgE, IL-5, IL-5Rα, IL-4Rα, and thymic stromal lymphopoietin, respectively.</div><div>In conclusion, the assessment of comorbidities in addition to biomarkers is essential for tailoring biologic therapies for severe asthma. Integrating comorbidity profiles into treatment strategies allows for a more precise and effective use of biologics, ultimately improving outcomes in complicated asthma cases.</div></div>","PeriodicalId":20934,"journal":{"name":"Respiratory investigation","volume":"64 1","pages":"Article 101337"},"PeriodicalIF":2.0,"publicationDate":"2025-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145616019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Successful tracheostomy tube removal following airway clearance using intrapulmonary percussive ventilation treatment after bilateral lung transplantation in a patient with idiopathic pleuroparenchymal fibroelastosis 特发性胸膜实质纤维弹性增生患者双侧肺移植术后使用肺内冲击通气清除气道后气管造口成功拔管一例

IF 2 Q2 RESPIRATORY SYSTEM

Respiratory investigation

Pub Date : 2025-11-25 DOI: 10.1016/j.resinv.2025.101336

Satoshi Hamada , Tomohiko Yamaguchi , Yohei Oshima , Yoshihiro Nishino , Satona Tanaka , Daisuke Nakajima , Toyohiro Hirai

Sputum management is a critical and potentially lethal issue in patients following lung transplantation. Here, we describe a patient with idiopathic pleuroparenchymal fibroelastosis who underwent tracheotomy after deceased donor bilateral lung transplantation, in whom we were unable to remove the tracheostomy tube due to difficulty in sputum evacuation. The tube was successfully removed following the subsequent initiation of intrapulmonary percussive ventilation (IPV) treatment combined with pulmonary rehabilitation. IPV has been widely used for several decades for treating pulmonary conditions, including chronic obstructive pulmonary disease, cystic fibrosis, and bronchiectasis. However, it should also be considered for airway clearance after lung transplantation.

痰液管理是肺移植术后患者的一个关键和潜在的致命问题。在这里，我们描述了一个特发性胸膜实质纤维弹性增生患者，他在死亡的双侧供体肺移植后接受了气管切开术，由于痰液难以排出，我们无法取出气管切开术管。在随后开始肺内冲击通气（IPV）治疗并结合肺部康复后，成功拔出了管子。几十年来，IPV被广泛用于治疗肺部疾病，包括慢性阻塞性肺疾病、囊性纤维化和支气管扩张。然而，肺移植后气道清除也应考虑。

引用次数: 0

Incidence and clinical features of venous thromboembolism in patients with lung cancer in Japan: results from the CS-Lung-003 prospective observational registry study 日本肺癌患者静脉血栓栓塞的发生率和临床特征：CS-Lung-003前瞻性观察登记研究的结果

IF 2 Q2 RESPIRATORY SYSTEM

Respiratory investigation

Pub Date : 2025-11-22 DOI: 10.1016/j.resinv.2025.11.011

Yukari Tsubata , Nobuhiro Kanaji , Mika Nakao , Takeshi Masuda , Masahiro Yamasaki , Masahiro Kodani , Nobuhisa Ishikawa , Toshiyuki Kozuki , Masaaki Inoue , Kazuya Nishii , Katsuyuki Hotta , Katsuyuki Kiura , Takeshi Isobe

Background

Venous thromboembolism (VTE) is a frequent complication of cancer-associated thrombosis, and its management is critical when considering cancer treatment selection and prognosis. The aim of this study was to investigate the incidence and risk factors for VTE in patients with lung cancer using the CS-Lung003 platform, a multicenter prospective observational study of advanced lung cancer.

Methods

Patients with a pathologic diagnosis of lung cancer at any stage were included. The incidence of VTE was calculated using the CS-Lung003 database, and risk factors were examined using logistic regression analysis.

Results

The analysis included 1744 patients (80 % male). Sixty patients (3.4 %) had VTE at/after enrollment in the CS-Lung003 trial. The median age was 69 years (range 63–76) in the group without VTE and 72 years (range 67–77) in the group with VTE. Adenocarcinoma was diagnosed in 58.7 % of patients in the group without VTE and 46.7 % in the group with VTE. Univariate analysis revealed male sex, body weight, and hypertension as risk factors for VTE. Overall survival was 29.1 months in the group without VTE and 30.6 months in the group with VTE. Among patients with stage IIIB–IV, the VTE group showed significantly longer overall survival compared with the non-VTE group (p = 0.041).

Conclusions

The incidence of VTE in this study was low, suggesting that there may have been patients with VTE complications that were not reported in the registry. In addition, most patients with VTE received therapeutic intervention; appropriate diagnosis and treatment may have allowed cancer treatment to continue. Appropriate diagnosis and treatment of VTE might allow lung cancer therapy continuation without compromising survival.

Clinical trial registry/registration number

UMIN-CTR/UMIN000026696.

静脉血栓栓塞（VTE）是癌症相关血栓形成的常见并发症，在考虑癌症治疗选择和预后时，其管理至关重要。本研究的目的是利用CS-Lung003平台，研究晚期肺癌多中心前瞻性观察性研究，探讨肺癌患者静脉血栓栓塞的发生率和危险因素。方法纳入病理诊断为肺癌的任何分期患者。采用CS-Lung003数据库计算静脉血栓栓塞发生率，采用logistic回归分析检查危险因素。结果纳入1744例患者，其中80%为男性。60名患者（3.4%）在CS-Lung003试验入组后出现静脉血栓栓塞。无静脉血栓栓塞组的中位年龄为69岁（63-76岁），有静脉血栓栓塞组的中位年龄为72岁（67-77岁）。无静脉血栓栓塞组的腺癌诊断率为58.7%，有静脉血栓栓塞组为46.7%。单因素分析显示，男性、体重和高血压是静脉血栓栓塞的危险因素。无静脉血栓栓塞组总生存期为29.1个月，有静脉血栓栓塞组总生存期为30.6个月。在IIIB-IV期患者中，VTE组的总生存期明显长于非VTE组（p = 0.041）。结论本研究中静脉血栓栓塞的发生率较低，提示可能存在未在登记中报告的静脉血栓栓塞并发症患者。此外，大多数VTE患者接受了治疗性干预；适当的诊断和治疗可能会使癌症治疗继续下去。适当的诊断和治疗静脉血栓栓塞可能使肺癌治疗继续而不影响生存。临床试验注册/注册号：umin - ctr /UMIN000026696。

{"title":"Incidence and clinical features of venous thromboembolism in patients with lung cancer in Japan: results from the CS-Lung-003 prospective observational registry study","authors":"Yukari Tsubata , Nobuhiro Kanaji , Mika Nakao , Takeshi Masuda , Masahiro Yamasaki , Masahiro Kodani , Nobuhisa Ishikawa , Toshiyuki Kozuki , Masaaki Inoue , Kazuya Nishii , Katsuyuki Hotta , Katsuyuki Kiura , Takeshi Isobe","doi":"10.1016/j.resinv.2025.11.011","DOIUrl":"10.1016/j.resinv.2025.11.011","url":null,"abstract":"<div><h3>Background</h3><div>Venous thromboembolism (VTE) is a frequent complication of cancer-associated thrombosis, and its management is critical when considering cancer treatment selection and prognosis. The aim of this study was to investigate the incidence and risk factors for VTE in patients with lung cancer using the CS-Lung003 platform, a multicenter prospective observational study of advanced lung cancer.</div></div><div><h3>Methods</h3><div>Patients with a pathologic diagnosis of lung cancer at any stage were included. The incidence of VTE was calculated using the CS-Lung003 database, and risk factors were examined using logistic regression analysis.</div></div><div><h3>Results</h3><div>The analysis included 1744 patients (80 % male). Sixty patients (3.4 %) had VTE at/after enrollment in the CS-Lung003 trial. The median age was 69 years (range 63–76) in the group without VTE and 72 years (range 67–77) in the group with VTE. Adenocarcinoma was diagnosed in 58.7 % of patients in the group without VTE and 46.7 % in the group with VTE. Univariate analysis revealed male sex, body weight, and hypertension as risk factors for VTE. Overall survival was 29.1 months in the group without VTE and 30.6 months in the group with VTE. Among patients with stage IIIB–IV, the VTE group showed significantly longer overall survival compared with the non-VTE group (p = 0.041).</div></div><div><h3>Conclusions</h3><div>The incidence of VTE in this study was low, suggesting that there may have been patients with VTE complications that were not reported in the registry. In addition, most patients with VTE received therapeutic intervention; appropriate diagnosis and treatment may have allowed cancer treatment to continue. Appropriate diagnosis and treatment of VTE might allow lung cancer therapy continuation without compromising survival.</div></div><div><h3>Clinical trial registry/registration number</h3><div>UMIN-CTR/UMIN000026696.</div></div>","PeriodicalId":20934,"journal":{"name":"Respiratory investigation","volume":"64 1","pages":"Article 101332"},"PeriodicalIF":2.0,"publicationDate":"2025-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145571142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Psychological palliative care for patients with interstitial lung disease in Japan: A secondary analysis of a National Survey of Japanese Respiratory Physicians 日本间质性肺病患者的心理姑息治疗：对日本呼吸内科医生全国调查的二次分析

IF 2 Q2 RESPIRATORY SYSTEM

Respiratory investigation

Pub Date : 2025-11-20 DOI: 10.1016/j.resinv.2025.11.009

Yoshinobu Matsuda , Tomoyuki Fujisawa , Tatsuya Morita , Masanori Mori , Norimichi Akiyama , Takafumi Koyauchi , Mitsunori Miyashita , Ryo Tachikawa , Keisuke Tomii , Hiromi Tomioka , Satoshi Hagimoto , Yasuhiro Kondoh , Yoshikazu Inoue , Takafumi Suda

Background

Patients with interstitial lung disease (ILD) often experience psychological symptoms. This study aimed to clarify the status of psychological support for patients with ILD in Japan.

Methods

We conducted a secondary analysis on a nationwide survey of Japanese respiratory physicians to assess psychological support availability, consultation departments, reasons for palliative care referrals, and opinions on insurance coverage for psychologist-led psychotherapy.

Results

Of 1332 respondents, 1023 managed patients with ILD in the previous year. Among them, 34.5 % reported no psychological support availability and 42.9 % reported insufficient support. Psychiatry or psychosomatic medicine departments were consulted by 77.3 %, and palliative care teams by 52.2 %. Anxiety (47.4 %) and depression (44.6 %) were the reasons for palliative care referral. Overall, 93.6 % considered insurance coverage for psychologist-led psychotherapy helpful or essential.

Conclusions

Most physicians lack adequate psychological support resources for ILD despite frequent psychological symptoms. Systematic development of support structures and insurance coverage are needed.

背景：间质性肺疾病（ILD）患者常出现心理症状。本研究旨在了解日本ILD患者的心理支持状况。方法我们对日本全国呼吸内科医生的调查进行了二次分析，以评估心理支持的可获得性、咨询部门、姑息治疗转诊的原因以及对心理医生主导的心理治疗的保险覆盖范围的意见。结果在1332名应答者中，1023名在前一年治疗过ILD患者。其中34.5%的人表示没有心理支持，42.9%的人表示支持不足。精神科或心身内科就诊的占77.3%，姑息治疗小组就诊的占52.2%。焦虑（47.4%）和抑郁（44.6%）是患者转诊姑息治疗的原因。总体而言，93.6%的人认为心理医生主导的心理治疗的保险范围是有益的或必要的。结论大多数医生对ILD缺乏足够的心理支持资源，但心理症状频繁。系统地发展支持结构和保险是必要的。

{"title":"Psychological palliative care for patients with interstitial lung disease in Japan: A secondary analysis of a National Survey of Japanese Respiratory Physicians","authors":"Yoshinobu Matsuda , Tomoyuki Fujisawa , Tatsuya Morita , Masanori Mori , Norimichi Akiyama , Takafumi Koyauchi , Mitsunori Miyashita , Ryo Tachikawa , Keisuke Tomii , Hiromi Tomioka , Satoshi Hagimoto , Yasuhiro Kondoh , Yoshikazu Inoue , Takafumi Suda","doi":"10.1016/j.resinv.2025.11.009","DOIUrl":"10.1016/j.resinv.2025.11.009","url":null,"abstract":"<div><h3>Background</h3><div>Patients with interstitial lung disease (ILD) often experience psychological symptoms. This study aimed to clarify the status of psychological support for patients with ILD in Japan.</div></div><div><h3>Methods</h3><div>We conducted a secondary analysis on a nationwide survey of Japanese respiratory physicians to assess psychological support availability, consultation departments, reasons for palliative care referrals, and opinions on insurance coverage for psychologist-led psychotherapy.</div></div><div><h3>Results</h3><div>Of 1332 respondents, 1023 managed patients with ILD in the previous year. Among them, 34.5 % reported no psychological support availability and 42.9 % reported insufficient support. Psychiatry or psychosomatic medicine departments were consulted by 77.3 %, and palliative care teams by 52.2 %. Anxiety (47.4 %) and depression (44.6 %) were the reasons for palliative care referral. Overall, 93.6 % considered insurance coverage for psychologist-led psychotherapy helpful or essential.</div></div><div><h3>Conclusions</h3><div>Most physicians lack adequate psychological support resources for ILD despite frequent psychological symptoms. Systematic development of support structures and insurance coverage are needed.</div></div>","PeriodicalId":20934,"journal":{"name":"Respiratory investigation","volume":"64 1","pages":"Article 101330"},"PeriodicalIF":2.0,"publicationDate":"2025-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145571139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of atropine and hydroxyzine pretreatment in contemporary bronchoscopy 阿托品和羟嗪预处理对当代支气管镜检查的影响

IF 2 Q2 RESPIRATORY SYSTEM

Respiratory investigation

Pub Date : 2025-11-20 DOI: 10.1016/j.resinv.2025.11.012

Kazuo Tsuchiya, Ryota Miyamoto, Tomo Tsunoda, Taisuke Ito, Takuro Akashi, Yoshiyuki Oyama, Masaki Ikeda

Background

Bronchoscopy is essential for diagnosing and managing respiratory diseases. However, secretions and airway reflexes can impair procedural quality and patient comfort. While anticholinergic pretreatment using agents such as atropine and hydroxyzine has historically mitigated these physiological responses, recent guidelines discourage their routine use because of concerns regarding hemodynamic changes and uncertain benefits. This study aimed to assess the efficacy of anticholinergic pretreatment during contemporary bronchoscopy.

Methods

We conducted a single-center, cross-sectional study comparing two cohorts of patients who underwent bronchoscopy with transbronchial and ultrasound-guided needle biopsies. Group A (n = 35) received pretreatment with intramuscular atropine (0.5 mg) and hydroxyzine (25 mg) between July 2022 and September 2023, while Group B (n = 35) underwent procedures without pretreatment between December 2024 and March 2025. Patient discomfort was evaluated using a visual analog scale. Propensity score adjustment with inverse probability of treatment weighting (IPTW) accounted for differences in baseline factors.

Results

Seventy patients were included (n = 35 per group). After IPTW adjustment, Group B reported greater distress from salivation and cough and lower willingness for repeat bronchoscopy (p = 0.03, p = 0.02, p = 0.001, respectively). Group B also showed higher use of lidocaine (p < 0.001). No significant differences in midazolam dosage or vital signs were observed among either group.

Conclusion

Anticholinergic pretreatment may reduce procedural discomfort, particularly that associated with secretions and airway reflexes, without evident adverse effects. Further randomized controlled trials are required to validate the role of pretreatment in contemporary bronchoscopy.

背景：支气管镜检查对于诊断和治疗呼吸系统疾病至关重要。然而，分泌物和气道反射会损害手术质量和患者舒适度。虽然使用阿托品和羟嗪等抗胆碱能预处理药物在历史上减轻了这些生理反应，但由于担心血流动力学变化和不确定的益处，最近的指南不鼓励常规使用这些药物。本研究旨在评估当代支气管镜检查中抗胆碱能预处理的疗效。方法：我们进行了一项单中心横断面研究，比较了两组接受支气管镜检查、经支气管和超声引导下穿刺活检的患者。A组（n = 35）在2022年7月至2023年9月期间接受了肌肉注射阿托品（0.5 mg）和羟嗪（25 mg）的预处理，而B组（n = 35）在2024年12月至2025年3月期间接受了没有预处理的手术。采用视觉模拟量表评估患者不适程度。倾向评分调整与治疗加权逆概率（IPTW）解释了基线因素的差异。结果共纳入70例患者，每组35例。调整IPTW后，B组患者的流涎和咳嗽症状加重，再次支气管镜检查意愿降低（p = 0.03, p = 0.02, p = 0.001）。B组的利多卡因使用率也较高（p < 0.001）。两组患者咪达唑仑剂量及生命体征无显著差异。结论抗胆碱能预处理可减少手术不适，特别是与分泌物和气道反射相关的不适，无明显不良反应。需要进一步的随机对照试验来验证预处理在当代支气管镜检查中的作用。

{"title":"Impact of atropine and hydroxyzine pretreatment in contemporary bronchoscopy","authors":"Kazuo Tsuchiya, Ryota Miyamoto, Tomo Tsunoda, Taisuke Ito, Takuro Akashi, Yoshiyuki Oyama, Masaki Ikeda","doi":"10.1016/j.resinv.2025.11.012","DOIUrl":"10.1016/j.resinv.2025.11.012","url":null,"abstract":"<div><h3>Background</h3><div>Bronchoscopy is essential for diagnosing and managing respiratory diseases. However, secretions and airway reflexes can impair procedural quality and patient comfort. While anticholinergic pretreatment using agents such as atropine and hydroxyzine has historically mitigated these physiological responses, recent guidelines discourage their routine use because of concerns regarding hemodynamic changes and uncertain benefits. This study aimed to assess the efficacy of anticholinergic pretreatment during contemporary bronchoscopy.</div></div><div><h3>Methods</h3><div>We conducted a single-center, cross-sectional study comparing two cohorts of patients who underwent bronchoscopy with transbronchial and ultrasound-guided needle biopsies. Group A (n = 35) received pretreatment with intramuscular atropine (0.5 mg) and hydroxyzine (25 mg) between July 2022 and September 2023, while Group B (n = 35) underwent procedures without pretreatment between December 2024 and March 2025. Patient discomfort was evaluated using a visual analog scale. Propensity score adjustment with inverse probability of treatment weighting (IPTW) accounted for differences in baseline factors.</div></div><div><h3>Results</h3><div>Seventy patients were included (n = 35 per group). After IPTW adjustment, Group B reported greater distress from salivation and cough and lower willingness for repeat bronchoscopy (p = 0.03, p = 0.02, p = 0.001, respectively). Group B also showed higher use of lidocaine (<em>p</em> < 0.001). No significant differences in midazolam dosage or vital signs were observed among either group.</div></div><div><h3>Conclusion</h3><div>Anticholinergic pretreatment may reduce procedural discomfort, particularly that associated with secretions and airway reflexes, without evident adverse effects. Further randomized controlled trials are required to validate the role of pretreatment in contemporary bronchoscopy.</div></div>","PeriodicalId":20934,"journal":{"name":"Respiratory investigation","volume":"64 1","pages":"Article 101333"},"PeriodicalIF":2.0,"publicationDate":"2025-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145571140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

High diagnostic yield and treatment impact of bronchoscopy in elderly lung cancer patients (≥ 80 years): A single-center retrospective study 老年肺癌患者（≥80岁）支气管镜检查的高诊断率和治疗效果：一项单中心回顾性研究

IF 2 Q2 RESPIRATORY SYSTEM

Respiratory investigation

Pub Date : 2025-11-19 DOI: 10.1016/j.resinv.2025.101335

Shingo Maeda , Takuma Ina , Atsuhiko Ota , Masaaki Matsunaga , Tomoya Horiguchi , Aki Ikeda , Ryoma Moriya , Takaya Sato , Chiaki Sawada , Yuko Oya , Shotaro Okachi , Yasuhiro Goto , Sumito Isogai , Naozumi Hashimoto , Masashi Kondo , Kazuyoshi Imaizumi

Background

Although bronchoscopic biopsy serves as a cornerstone for diagnosing lung cancer in elderly patients, whether this procedure leads to clinically relevant outcomes is still unclear. This study aimed to clarify the clinical significance of diagnostic bronchoscopy in lung cancer patients aged ≥80 years.

Methods

We retrospectively analyzed 803 patients diagnosed with lung cancer who underwent bronchoscopy at our hospital from April 2015 to March 2019. Those aged ≥80 years and <80 years were classified as the elderly group (n = 154) and young group (n = 649), respectively.

Results

The diagnostic yield of bronchoscopy in the elderly and young groups was 92.9 % and 83.5 %, respectively; complication rates were 9.6 % and 7.2 %. Approximately 89 % of the patients in the elderly group received specific lung cancer treatment. The 5-year survival rates for elderly and young patients who underwent surgery were 74.5 % and 78.2 %, respectively. In the elderly group, 11 % of the patients chose best supportive care (BSC) only, compared with 2 % in the young group. Notably, patients with non-diagnostic bronchoscopic results selected BSC more frequently in the elderly versus young groups (30.4 % versus 0 %, respectively).

Conclusions

Bronchoscopy in elderly patients with lung cancer demonstrated a high diagnostic yield and an acceptable safety profile, enabling specific treatments in the majority of cases. These findings support the clinical usefulness of bronchoscopy in guiding treatment decisions for elderly patients. However, non-diagnostic results were associated with a higher likelihood of BCS, highlighting the importance of achieving a definitive diagnosis in this population.

背景：尽管支气管镜活检是诊断老年患者肺癌的基础，但该手术是否会导致临床相关的结果尚不清楚。本研究旨在阐明≥80岁肺癌患者诊断性支气管镜检查的临床意义。方法：回顾性分析2015年4月至2019年3月在我院行支气管镜检查的803例肺癌患者。≥80岁及结果：老年组支气管镜诊断率为92.9%，青年组为83.5%；并发症发生率分别为9.6%和7.2%。大约89%的老年组患者接受了特定的肺癌治疗。老年和年轻患者手术后的5年生存率分别为74.5%和78.2%。在老年组中，11%的患者只选择了最佳支持治疗（BSC），而在年轻组中，这一比例为2%。值得注意的是，非诊断性支气管镜检查结果的患者在老年人中比年轻人更频繁地选择BSC（分别为30.4%和0%）。结论：支气管镜检查在老年肺癌患者中具有较高的诊断率和可接受的安全性，可在大多数病例中进行特异性治疗。这些发现支持支气管镜检查在指导老年患者治疗决策中的临床应用。然而，非诊断性结果与BCS的可能性较高相关，强调了在该人群中获得明确诊断的重要性。

{"title":"High diagnostic yield and treatment impact of bronchoscopy in elderly lung cancer patients (≥ 80 years): A single-center retrospective study","authors":"Shingo Maeda , Takuma Ina , Atsuhiko Ota , Masaaki Matsunaga , Tomoya Horiguchi , Aki Ikeda , Ryoma Moriya , Takaya Sato , Chiaki Sawada , Yuko Oya , Shotaro Okachi , Yasuhiro Goto , Sumito Isogai , Naozumi Hashimoto , Masashi Kondo , Kazuyoshi Imaizumi","doi":"10.1016/j.resinv.2025.101335","DOIUrl":"10.1016/j.resinv.2025.101335","url":null,"abstract":"<div><h3>Background</h3><div>Although bronchoscopic biopsy serves as a cornerstone for diagnosing lung cancer in elderly patients, whether this procedure leads to clinically relevant outcomes is still unclear. This study aimed to clarify the clinical significance of diagnostic bronchoscopy in lung cancer patients aged ≥80 years.</div></div><div><h3>Methods</h3><div>We retrospectively analyzed 803 patients diagnosed with lung cancer who underwent bronchoscopy at our hospital from April 2015 to March 2019. Those aged ≥80 years and <80 years were classified as the elderly group (n = 154) and young group (n = 649), respectively.</div></div><div><h3>Results</h3><div>The diagnostic yield of bronchoscopy in the elderly and young groups was 92.9 % and 83.5 %, respectively; complication rates were 9.6 % and 7.2 %. Approximately 89 % of the patients in the elderly group received specific lung cancer treatment. The 5-year survival rates for elderly and young patients who underwent surgery were 74.5 % and 78.2 %, respectively. In the elderly group, 11 % of the patients chose best supportive care (BSC) only, compared with 2 % in the young group. Notably, patients with non-diagnostic bronchoscopic results selected BSC more frequently in the elderly versus young groups (30.4 % versus 0 %, respectively).</div></div><div><h3>Conclusions</h3><div>Bronchoscopy in elderly patients with lung cancer demonstrated a high diagnostic yield and an acceptable safety profile, enabling specific treatments in the majority of cases. These findings support the clinical usefulness of bronchoscopy in guiding treatment decisions for elderly patients. However, non-diagnostic results were associated with a higher likelihood of BCS, highlighting the importance of achieving a definitive diagnosis in this population.</div></div>","PeriodicalId":20934,"journal":{"name":"Respiratory investigation","volume":"64 1","pages":"Article 101335"},"PeriodicalIF":2.0,"publicationDate":"2025-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145564599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Critical appraisal of “Effects of Daikin air purifiers on asthma control and pulmonary function: A multicenter, single-arm, observational pilot study” “大金空气净化器对哮喘控制和肺功能的影响：一项多中心、单臂、观察性初步研究”的批判性评价

IF 2 Q2 RESPIRATORY SYSTEM

Respiratory investigation

Pub Date : 2025-11-18 DOI: 10.1016/j.resinv.2025.11.004

Parth Aphale, Himanshu Shekhar, Shashank Dokania

引用次数: 0